At 54 weeks in the STOP-HS1 and STOP-HS2 trials, up to 71.4% of patients taking povorcitinib achieved at least a 50% reduction from baseline in the total abscess and inflammatory ...

ADJUNCTIVE narrowband ultraviolet B (NB-UVB) phototherapy may help restore clinical response in patients with chronic plaque psoriasis who experience secondary failure to adalimumab, according to a ...

BIMEKIZUMAB showed the strongest short-term efficacy among hidradenitis suppurativa biologics in trials assessed at Week 12 to 16. Hidradenitis Suppurativa Biologics Compared in a Network Meta ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...

"SELECT-SWITCH is the first head-to-head trial comparing TNF inhibitor cycling with switching to the JAK inhibitor upadacitinib," said lead study investigator Eduardo Mysler, M.D., rheumatologist and ...

Upadacitinib demonstrated greater clinical efficacy than adalimumab for treating rheumatoid arthritis, regardless of patients’ baseline cardiovascular risks. Upadacitinib 15 mg once daily demonstrates ...

Biosimilar IBI303 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates. Patients with ankylosing spondylitis ...

Sonelokimab, lutikizumab, and adalimumab showed the highest HiSCR-50 response rates in moderate to severe hidradenitis suppurativa, per a network meta-analysis in JAMA Dermatology. In a network ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...

Treatment with guselkumab in patients with plaque psoriasis was associated with improvements in 3 biomarkers, yet greater improvements were seen with adalimumab and similar improvements were seen with ...

Patients with moderate to severe plaque psoriasis who switched between the biosimilar CT-917 and reference adalimumab vs those with continuous adalimumab treatment had similar pharmacokinetic, ...

Non-infectious uveitis is a rare immune-mediated condition in children and is often treated with the tumor necrosis factor inhibitor adalimumab. Discontinuing the drug may be considered when remission ...